dilat
cardiomyopathi
dcm
clinic
diagnosi
character
left
ventricular
biventricular
dilat
impair
contract
explain
abnorm
load
condit
exampl
hypertens
valvular
heart
diseas
coronari
arteri
diseas
mutat
sever
gene
caus
dcm
includ
gene
encod
structur
compon
sarcomer
desmosom
nongenet
form
dcm
result
differ
aetiolog
includ
inflamm
myocardium
due
infect
mostli
viral
exposur
drug
toxin
allergen
system
endocrin
autoimmun
diseas
heterogen
aetiolog
clinic
present
dcm
make
correct
time
diagnosi
challeng
echocardiographi
imag
techniqu
requir
assess
ventricular
dysfunct
advers
myocardi
remodel
immunolog
histolog
analys
endomyocardi
biopsi
sampl
indic
inflamm
infect
suspect
dcm
eventu
lead
impair
contractil
standard
approach
prevent
treat
heart
failur
firstlin
treatment
patient
dcm
cardiac
resynchron
therapi
implant
cardioverterdefibril
may
requir
prevent
lifethreaten
arrhythmia
addit
identifi
probabl
caus
dcm
help
tailor
specif
therapi
improv
prognosi
improv
aetiologydriven
person
approach
clinic
care
benefit
patient
dcm
new
diagnost
tool
serum
biomark
enabl
earli
diagnosi
treatment
wwwnaturecomnrdp
p
r
e
r
p
r
e
r
p
r
e
r
p
r
e
r
natur
review
diseas
primer
articl
citat
id
p
r
e
r
p
r
e
r
natur
review
diseas
primer
articl
citat
id
p
r
e
r
p
r
e
r
p
r
e
r
cardiomyopathi
disord
cardiac
muscl
caus
mechan
andor
electr
dysfunct
result
dilat
hypertroph
restrict
pathophysiolog
dilat
cardiomyopathi
dcm
nonischaem
heart
muscl
diseas
structur
function
myocardi
abnorm
clinic
pictur
dcm
defin
left
biventricular
dilat
systol
dysfunct
absenc
coronari
arteri
diseas
hypertens
valvular
diseas
congenit
heart
diseas
american
heart
associ
classifi
dcm
genet
mix
acquir
wherea
european
societi
cardiolog
esc
group
cardiomyopathi
famili
genet
nonfamili
nongenet
form
defin
dcm
seriou
cardiac
disord
structur
function
abnorm
heart
muscl
lead
substanti
morbid
mortal
owe
complic
heart
failur
arrhythmia
decad
research
reveal
divers
aetiolog
dcm
includ
genet
mutat
infect
inflamm
autoimmun
diseas
exposur
toxin
endocrin
neuromuscular
caus
box
idiopath
famili
diseas
commonli
report
caus
dcm
accur
identifi
aetiolog
dcm
wide
array
noninvas
invas
examin
need
wide
variabl
exist
global
avail
advanc
diagnost
tool
genet
test
inborn
metabol
error
exampl
comprehens
cardiac
imag
thu
mani
case
dcm
could
classifi
idiopath
fact
thorough
evalu
would
enabl
precis
diagnosi
underli
aetiolog
ongo
advanc
genet
sequenc
molecular
method
increas
resourc
avail
clinician
determin
diseas
aetiolog
provid
tailor
risk
stratif
resourc
improv
patient
care
could
potenti
revers
diseas
progress
complic
clinic
heterogen
present
dcm
differ
exist
accord
sex
age
onset
acut
progress
present
rate
progress
risk
develop
overt
heart
failur
probabl
sudden
cardiac
death
final
inherit
predisposit
environment
factor
play
import
part
natur
histori
diseas
small
patient
populationbas
studi
minnesota
usa
estim
ageadjust
sexadjust
incid
idiopath
dcm
per
personyear
preval
idiopath
dcm
studi
estim
per
individu
review
preval
dcm
estim
per
individu
basi
recent
clinic
trial
relat
data
result
particularli
relev
reliabl
popu
lationbas
studi
preval
hypertroph
cardiomyopathi
estim
least
per
individu
review
articl
estim
dcm
least
common
popul
hypertroph
cardiomyopathi
global
burden
diseas
studi
estim
global
preval
cardiomyopathi
million
case
increas
year
estim
mortal
associ
cardiomyopathi
per
global
popul
correspond
death
increas
per
ref
estim
may
affect
bia
due
misclassif
miss
incomplet
data
among
other
addit
need
intern
consortia
group
cohort
patient
overcom
issu
low
number
event
followup
annual
chang
cardiomyopathi
percentag
death
shown
fig
caus
heart
failur
aris
dcm
occur
pump
failur
due
dilat
wherea
sudden
cardiac
death
arrhythmia
account
remain
surviv
patient
dcm
develop
heart
failur
improv
time
develop
countri
improv
surviv
attribut
larg
part
increas
avail
use
angiotensinconvert
enzym
ace
inhibitor
implant
cardioverterdefibril
icd
heart
transplant
howev
intervent
avail
world
popul
furthermor
effect
medic
ventricular
devic
heart
transplant
natur
histori
dcm
well
character
despit
advanc
manag
heart
failur
patient
dcm
still
substanti
mortal
risk
develop
congest
heart
failur
higher
black
white
individu
find
explain
confound
variabl
hypertens
socioeconom
factor
sever
studi
report
rel
risk
mortal
dcm
black
compar
agematch
white
peopl
black
ethnic
also
associ
poor
outcom
acut
idiopath
dcm
euroheart
failur
survey
ii
examin
data
accord
sex
found
dcm
occur
often
men
women
howev
epidemiolog
studi
report
data
accord
sex
studi
compar
sex
differ
dcm
phenotyp
sever
outcom
lack
populationbas
epidemiolog
studi
idiopath
dcm
minnesota
report
male
femal
ratio
ref
multicentr
imac
intervent
myocard
acut
cardiomyopathi
studi
men
left
ventricular
lv
eject
fraction
lvef
fraction
volum
fluid
eject
left
ventricl
contract
physiolog
valu
month
heart
failur
symptom
durat
myocard
inflamm
myocardium
acut
onset
idiopath
dcm
idiopath
dcm
month
symptom
durat
wors
recoveri
assess
new
york
heart
associ
nyha
classif
reduc
transplantfre
surviv
women
find
similar
data
patient
heart
failur
gener
multisit
studi
usa
canada
dcm
common
form
cardiomyopathi
among
children
individu
year
age
idiopath
dcm
wherea
dcm
due
known
caus
myocard
neuromuscular
diseas
annual
incid
dcm
children
rang
per
personyear
annual
incid
higher
boy
girl
black
individu
white
infant
year
age
older
children
north
america
children
dcm
progress
heart
failur
receiv
heart
transplant
within
year
diagnosi
figur
increas
year
diagnosi
risk
factor
increas
risk
death
heart
transplant
includ
congest
heart
failur
increas
lv
endsystol
dimens
zscore
paramet
often
use
children
surrog
lvef
diagnosi
older
age
diagnosi
anim
model
demonstr
lv
dilat
result
remodel
fibrosi
similarli
patient
dcm
evid
scar
tissu
left
ventricl
assum
spheric
shape
pathophysiolog
chang
includ
decreas
stroke
volum
blood
volum
pump
left
ventricl
contract
cardiac
output
amount
blood
pump
heart
per
minut
impair
ventricular
fill
increas
enddiastol
pressur
amount
blood
ventricl
relax
measur
dilat
compensatori
chang
vascular
system
includ
increas
system
vascular
resist
decreas
arteri
complianc
increas
venou
pressur
circul
blood
volum
cardiac
preload
stretch
heart
wall
contract
afterload
forc
need
contract
eject
blood
heart
increas
increas
afterload
result
elev
wall
stress
diastol
involv
activ
relax
earli
diastol
passiv
complianc
midtol
diastol
dcm
diastol
dysfunct
affect
compon
accompani
reduct
systol
function
impair
ventricular
relax
result
reduc
rapid
ventricular
fill
wide
spectrum
potenti
caus
dcm
oftenslow
progress
initi
cardiac
damag
eventu
sign
symptom
heart
failur
make
interven
diseas
process
earli
enough
prevent
irrevers
damag
particularli
challeng
develop
nextgener
sequenc
made
possibl
new
era
human
genet
genom
clinic
research
purpos
sever
gene
mutat
associ
develop
dcm
identifi
tabl
howev
gene
gene
variant
curat
distinguish
pathogenet
nonpathogenet
gene
specif
gene
variant
remain
crucial
unresolv
issu
moreov
extent
genet
aetiolog
sporad
dcm
remain
unresolv
final
interrelationship
environment
genet
caus
dcm
remain
minim
studi
although
data
show
alcohol
exposur
facilit
develop
dcm
individu
rare
variant
establish
dcmassoci
gene
famili
dcm
commonli
defin
least
two
close
relat
firstdegre
seconddegre
famili
member
meet
diagnost
criteria
idiopath
dcm
substanti
evid
avail
indic
famili
dcm
consid
genet
basi
clinic
genet
test
servic
larg
panel
gene
implic
dcm
routin
avail
patient
dcm
famili
member
familybas
studi
establish
patient
dcm
may
diagnos
famili
dcm
famili
member
undergo
clinic
screen
larg
multigener
famili
dcm
pedigre
histor
start
point
dcmassoci
gene
discoveri
multigener
pedigre
provid
robust
statist
genet
evid
variant
causal
dcmassoci
gene
gene
commonli
known
caus
dcm
includ
lmna
ref
ref
ttn
ref
ref
other
identifi
initi
larg
dcm
pedigre
fig
ttn
truncat
mutat
common
caus
dcm
occur
famili
case
dcm
sporad
case
reader
encourag
view
extens
dcmassoci
gene
list
review
articl
although
genet
basi
famili
dcm
well
establish
case
dcm
seem
sporad
even
famili
member
patient
newli
diagnos
idiopath
dcm
clinic
screen
famili
member
evid
dcm
therefor
patient
eventu
diagnos
nonfamili
sporad
dcm
date
publish
larg
multicentr
studi
famili
whose
member
systemat
clinic
screen
dcm
also
undergon
exom
genom
sequenc
identifi
possibl
genet
caus
multisit
studi
fund
us
nation
heart
lung
blood
institut
underway
test
hypothesi
dcm
whether
famili
nonfamili
mostli
rare
variant
genet
basi
curat
strength
evid
suggest
gene
mutat
caus
dcm
fundament
clinic
care
one
adjud
variant
pathogenet
probabl
pathogenet
relev
gene
caus
dcm
uncertain
gene
curat
also
fundament
import
discoveri
dcmassoci
gene
level
evid
requir
chang
classif
gene
gene
uncertain
signific
dcm
gene
confirm
relev
one
routin
includ
clinic
test
panel
unclear
ideal
gene
discoveri
scenario
one
larg
multigener
dcm
pedigre
numer
affect
famili
member
sever
smaller
famili
famili
rare
gene
variant
unaffect
individu
carri
variant
addit
support
evid
would
genomewid
sequenc
exclud
presenc
rare
variant
establish
dcmassoci
gene
howev
scenario
rare
achiev
dcm
usual
lethal
condit
larg
famili
exist
reason
studi
includ
cohort
individu
patient
dcm
whose
dcmassoci
candid
gene
sequenc
rare
code
variant
identifi
number
individu
rare
variant
gene
compar
number
individu
larg
publicli
access
refer
data
set
also
carri
rare
code
variant
type
largest
public
databas
genom
aggreg
databas
gnomad
expans
exom
aggreg
consortium
exac
databas
exom
genom
sequenc
individu
gener
popul
presum
known
dcm
respons
need
systemat
approach
gene
curat
clingen
consortium
larg
collabor
effort
sponsor
us
nation
human
genom
research
institut
publish
systemat
approach
integr
genet
experiment
evid
genediseas
relationship
approach
use
semiquantit
score
system
valid
across
sever
mendelian
diseas
result
evid
support
associ
specif
gene
diseas
classifi
definit
strong
moder
limit
absent
conflict
approach
use
clingen
cardiovascular
diseas
work
group
gene
curat
hypertroph
cardiomyopathi
curat
gene
associ
arrhythmogen
right
ventricular
cardiomyopathi
dcm
underway
like
gene
curat
variant
curat
also
challeng
even
wellestablish
dcmassoci
gene
patient
dcm
sequenc
establish
candid
dcmassoci
gene
lead
identif
rare
variat
exampl
allel
frequenc
commonli
rare
variant
uniqu
howev
presenc
uniqu
rare
variant
necessarili
assign
causal
dcm
vari
ant
furthermor
plethora
rare
variant
identifi
exom
genom
sequenc
challeng
prior
variant
adjud
approach
avail
larg
genet
data
set
divers
ethnic
group
brought
new
challeng
focu
variant
consid
rare
comparison
control
dna
sampl
hundr
individu
common
previous
thought
unlik
diseas
caus
studi
leverag
exac
databas
exom
sequenc
shown
frequenc
rare
variant
control
popul
mirror
gene
propos
relev
hypertroph
cardiomyopathi
therebi
question
relev
attribut
variant
paradigm
also
applic
dcm
american
colleg
medic
genet
substanti
revis
approach
variant
interpret
clinic
sequenc
make
approach
applic
standard
much
rigor
overal
effect
make
interpret
conserv
adjud
variant
pathogenet
probabl
pathogenet
variant
consid
probabl
pathogenet
probabl
variant
pathogenet
variant
meet
rigor
standard
note
variant
uncertain
signific
furthermor
recent
develop
rapidli
expand
databas
clinvar
assert
variant
patholog
publicli
access
databas
clingen
interact
clinvar
popul
clinvar
curat
variant
medic
relev
gene
includ
associ
cardiomyopathi
final
frontier
dcm
genet
may
deciph
interrelationship
genet
diseas
pathway
establish
nongenet
diseas
mechan
includ
exampl
immunolog
infecti
aetiolog
larg
studi
link
genet
nongenet
caus
unifi
research
approach
yet
accomplish
damag
myocardium
whether
genet
environment
caus
trigger
inflamm
recruit
immun
cell
heart
repair
myocardium
common
caus
inflammatori
dcm
infect
autoimmun
patholog
examin
myocardi
biopsi
sampl
autopsi
patient
dcm
frequent
uncov
evid
inflammatori
cell
infiltr
gene
express
pattern
compat
immun
cell
activ
immun
cell
contribut
remodel
includ
mast
cell
macrophag
macrophag
also
known
altern
activ
macrophag
myeloidderiv
suppressor
cell
helper
h
h
cell
case
autoimmun
aetiolog
b
cell
produc
autoantibodi
form
immun
complex
selfantigen
complement
compon
immun
cell
releas
cytokin
transform
growth
tumour
necrosi
factor
tnf
among
mediat
promot
remodel
collagen
deposit
fibrosi
fibrosi
consequ
inflamm
site
tissu
damag
characterist
patholog
featur
dcm
asid
dilat
region
dysfunct
andor
volum
overload
lead
increas
cardiac
workload
wall
stress
activ
fetal
gene
myocyt
revers
fetal
program
myofibroblast
mechan
consequ
caus
fibrosi
time
fibrot
scar
tissu
eventu
replac
damag
tissu
therebi
stiffen
heart
amplifi
progress
dilat
heart
failur
infect
believ
account
aetiolog
dcm
typic
associ
myocard
demonstr
anim
model
patient
one
common
group
virus
associ
dcm
enterovirus
includ
coxsackieviru
group
b
particular
box
adenovirus
herpesvirus
also
commonli
found
patient
dcm
less
well
establish
role
parvovirus
associ
dcm
patient
analysi
myocardi
biopsi
sampl
patient
dcm
identifi
molecular
evid
viral
genom
evid
viral
prolifer
posit
identif
viral
genom
biopsi
associ
morerapid
progress
dcm
wors
clinic
outcom
autoimmun
sever
line
evid
indic
dcm
result
autoimmun
diseas
accord
rosewitebski
criteria
evid
includ
presenc
cardiac
immun
cell
infiltr
biopsi
sampl
abnorm
express
hla
class
ii
andor
adhes
molecul
essenti
initi
immun
respons
mediat
hla
class
ii
therefor
use
biomark
identifi
autoimmun
diseas
cardiac
microvascular
endothelium
absenc
viral
genom
detect
biopsi
sampl
index
patient
famili
member
increas
serum
level
cardiac
autoantibodi
patient
rel
experiment
induc
anim
model
dcm
immun
recogn
autoantigen
also
found
patient
dcm
respons
immunosuppress
immunomodul
patient
suspect
autoimmun
dcm
furthermor
autoimmun
diseas
system
lupu
erythematosu
system
sclerosi
rheumatoid
arthriti
rare
caus
dcm
occur
case
cardiacspecif
autoantibodi
occur
patient
dcm
rel
directli
influenc
myocyt
function
prognosi
diseas
patient
inflammatori
dcm
may
famili
associ
hla
antigen
describ
landmark
multicentr
european
genomewid
associ
studi
studi
report
hla
risk
locu
dcm
consist
autoimmun
aetiolog
dcm
probabl
repres
end
result
one
aetiolog
agent
individu
patient
multipl
hit
cascad
involv
geneenviron
interact
best
depict
applic
new
complex
classif
moge
cardiac
heavychain
isoform
frequent
recogn
autoantigen
autoantibodi
seem
direct
function
pathogenet
role
furthermor
immun
anim
autoantigen
identifi
patient
dcm
adrenerg
receptor
muscarin
acetylcholin
receptor
cardiac
myosin
heavi
chain
cardiac
troponin
lead
cardiac
abnorm
reproduc
dcm
phenotyp
note
myocardi
patholog
produc
transfer
immun
compon
one
experiment
anim
anoth
passiv
transfer
antibodi
purifi
rat
immun
cardiac
myosin
lead
depo
sition
antibodi
myocardium
myocyt
apoptosi
produc
cardiomyopathi
recipi
anim
mous
model
autoimmun
myocard
dcm
induc
immun
heavi
chain
kinas
also
known
mitogenactiv
protein
kinas
kinas
kinas
mediat
rapid
wnt
protein
secret
result
myofibroblast
differenti
myocardi
fibrosi
progress
suggest
possibl
mechan
autoimmun
promot
remodel
lead
dcm
myosin
heavi
chain
relev
tabl
mutat
gene
encod
cardiac
troponin
encod
also
link
directli
disord
forc
gener
mutat
predict
disrupt
actinmyosin
bind
crossbridg
function
wherea
mutat
ttn
chang
viscoelast
properti
mutat
noncontractil
protein
exampl
cochaperon
heat
shock
protein
heat
shock
cognat
chaperon
protein
encod
may
induc
defect
cell
signal
pathway
modifi
cardiac
respons
mutat
phospholamban
encod
pln
key
calcium
signal
protein
directli
link
abnorm
contractil
variant
desmosom
protein
includ
desmin
encod
de
desmocollin
encod
desmoglein
encod
desmoplakin
encod
dsp
plakophilin
encod
commonli
associ
arrhythmogen
right
ventricular
cardiomyopathi
mutat
gene
also
implic
dcm
patient
genet
dcm
particular
gene
defect
may
suggest
cardiac
conduct
abnorm
exampl
variant
lamin
ac
lmna
part
protein
structur
associ
inner
nuclear
membran
associ
high
rate
conduct
system
diseas
ventricular
arrhythmia
sudden
cardiac
death
howev
case
dcm
specif
distinguish
phenotyp
featur
sarcoplasmicendoplasm
reticulum
calcium
atpas
adapt
ref
springer
natur
limit
autoantigen
patient
autoimmun
dcm
pharmacolog
target
wnt
protein
might
repres
promis
therapeut
approach
futur
chronic
alcohol
abus
import
caus
dcm
occur
often
men
year
age
heavi
consum
alcohol
least
year
proport
alcohol
cardiomyopathi
among
cardiomyopathi
death
estim
global
alcohol
dcm
occur
often
men
women
studi
anim
demonstr
acut
chronic
ethanol
administr
impair
cardiac
contractil
decreas
contractil
protein
heavi
chain
metabolit
alcohol
acetaldehyd
alter
cellular
calcium
magnesium
phosphat
homeo
stasi
impair
mitochondri
respir
exampl
damag
myocardium
alcohol
also
recruit
inflammatori
cell
heart
longterm
abus
cocain
also
known
caus
dcm
lethal
arrhythmia
depress
lv
function
report
individu
use
cocain
cardiac
symptom
cocain
believ
caus
lv
dysfunct
increas
releas
catecholamin
directli
toxic
cardiomyocyt
lead
necrosi
similar
effect
alcohol
cocain
also
caus
myocyt
death
damag
mitochondria
myocard
report
patient
die
suspect
cocain
overdos
suggest
myocardi
inflamm
may
lead
dcm
least
case
dcm
occur
advers
effect
cancer
chemotherapeut
agent
anthracyclin
anthracyclin
frequent
caus
dcm
includ
doxorubicin
epirubicin
idarubicin
doxorubicin
wide
use
effect
chemotherapi
treatment
mani
adult
paediatr
cancer
howev
one
advers
effect
cumul
doserel
progress
myocardi
damag
may
lead
dcm
congest
heart
failur
doxorubicin
bind
dna
type
ii
topoisomeras
lead
dna
doublestrand
break
transcriptom
chang
result
mitochondri
dysfunct
reactiv
oxygen
speci
gener
cardiac
cell
death
children
cancer
receiv
anthracyclin
result
surviv
develop
least
form
cardiac
dysfunct
lead
cardiomyocyt
necrosi
apoptosi
hypertrophi
fibrosi
lv
dysfunct
dcm
heart
failur
endomyocardi
biopsi
emb
sampl
reveal
featur
cardiotox
cytosol
vacuol
lysi
myofibril
cellular
swell
troponin
marker
myocardi
injuri
use
serum
biomark
doxorubicin
cardiotox
predict
progress
dcm
male
sex
import
risk
factor
develop
heart
failur
follow
number
cardiovascular
condit
includ
dcm
howev
clinic
studi
examin
sex
differ
incid
pathogenet
mechan
dcm
specif
one
studi
examin
sex
differ
pathogenet
mechan
dcm
men
acut
dcm
found
higher
express
protein
associ
apoptosi
women
higher
express
level
correl
lower
lvef
anim
model
myocard
progress
dcm
depend
sex
race
mous
strain
male
suscept
mous
strain
develop
fibrosi
dcm
acut
myocard
wherea
femal
develop
mild
dcm
base
echocardiographi
similar
find
observ
patient
sever
clinic
symptomat
myocard
men
twice
like
women
present
evid
myocardi
fibrosi
assess
cardiac
mri
anim
studi
reveal
pathogenet
mechan
lead
cardiac
remodel
dcm
similar
regardless
caus
damag
myocardium
promot
testosteron
male
anim
testosteron
found
increas
number
macrophag
express
also
known
integrin
tolllik
receptor
anim
model
lead
increas
cardiac
inflamm
remodel
dcm
sex
hormon
alter
cardiac
function
bind
androgen
oestrogen
receptor
cardiac
vascular
endotheli
cell
smooth
muscl
cell
fibroblast
myocyt
addit
bind
sex
hormon
receptor
directli
alter
function
immun
cell
platelet
influenc
type
cardiac
inflamm
remodel
thrombosi
involv
dcm
mani
inflammatori
cell
cytokin
drive
dilat
occur
often
menalso
predispos
patient
dcm
thrombo
embol
event
includ
complement
platelet
activ
importantli
women
higher
level
oestrogen
receptor
arteri
men
activ
receptor
prevent
cardiomyocyt
apoptosi
inhibit
cardiac
damag
induc
reactiv
oxygen
speci
reduc
cardiac
hypertrophi
fibrosi
women
anim
model
androgen
promot
hypertrophi
overal
underli
sex
differ
cardiac
pathophysiolog
immun
respons
cardiac
injuri
believ
lead
observ
sex
differ
dcm
heart
failur
clinic
present
dcm
gener
unrel
underli
aetiolog
rang
dyspnoea
swollen
leg
ankl
stomach
fatigu
chest
pain
caus
reduc
oxygen
level
reach
heart
arrhythmia
acut
decompens
cardiogen
shock
sign
symptom
dcm
mainli
relat
degre
lv
biventricular
systol
dysfunct
lead
pump
failur
heart
failur
sign
symptom
may
fulmin
acut
subacut
chronic
addit
atyp
chest
pain
palpit
may
present
dcm
typic
diagnos
year
age
dilat
chamber
readili
identifi
use
echocardiographi
diagnost
criteria
lv
enddiastol
volum
diamet
sd
normal
accord
normogram
zscore
sd
correct
age
bodi
surfac
area
eject
fraction
cardiac
catheter
may
perform
rule
coexist
coronari
arteri
diseas
cardiac
mri
may
assist
imag
dilat
use
determin
presenc
oedema
andor
fibrosi
suggest
inflamm
electrocardiographi
ecg
patient
dcm
may
remark
normal
abnorm
rang
isol
wave
chang
left
bundl
branch
block
prolong
atrioventricular
conduct
occur
sinu
tachycardia
supraventricular
arrhythmia
common
patient
nonsustain
ventricular
tachycardia
ambulatori
holter
monitor
captur
prematur
ventricular
complex
sustain
nonsustain
ventricular
tachycardia
import
especi
differenti
diagnosi
arrhythmogen
cardiomyopathi
diagnost
accuraci
depend
combin
convent
noninvas
invas
cardiolog
examin
molecular
noncardiac
paramet
includ
genet
analys
comprehens
approach
also
need
determin
aetiolog
dcm
describ
see
section
autoimmun
differ
serum
autoantibodi
cardiacspecif
musclespecif
autoantigen
found
myocard
autoimmun
dcm
autoantibodi
might
direct
pathogenet
role
genet
form
dcm
suggest
presenc
clinic
trait
sometim
known
diagnost
red
flag
rare
import
sign
symptom
indic
specif
multisystem
diseas
genotyp
includ
abnorm
skin
pigment
skelet
myopathi
neurosensori
disord
exampl
deaf
blind
individu
diagnos
idiopath
dcm
genet
aetiolog
consid
thu
basic
evalu
patient
includ
detail
famili
histori
well
clinic
screen
firstdegre
rel
nextgener
sequenc
method
wholeexom
wholegenom
sequenc
emerg
moder
inexpens
approach
diagnosi
clinic
research
implic
inherit
cardiomyopathi
includ
dcm
genet
heterogen
associ
rare
mutat
larg
number
gene
mani
mutat
result
similar
phenotyp
therefor
phenotyp
differ
underli
mutat
even
absenc
identifi
pathogenet
mutat
firstdegre
rel
period
ecg
echocardiographi
detect
earli
sign
dcm
addit
genet
variat
numer
factor
affect
gene
express
therefor
determin
gene
mutat
manifest
genotyp
frequent
equat
phenotyp
environment
epigenet
influenc
gene
express
exampl
mutat
promot
cardiomyocyt
damag
recruit
proinflammatori
respons
promot
remodel
dcm
thu
assess
famili
dcm
would
bene
fit
improv
understand
influenc
environment
epigenet
factor
imag
techniqu
doppler
echocardiographi
remain
primari
method
analys
cardiac
function
undergird
diagnost
criteria
heart
muscl
diseas
thu
patient
unexplain
suspect
moder
sever
heart
failur
symptom
undergo
echocardiographi
first
present
followup
echocardiogram
featur
indic
specif
aetiolog
howev
echocardiographi
definit
establish
underli
caus
dcm
exampl
wall
motion
abnorm
nonischaem
origin
suggest
myocard
addit
lv
remodel
function
mitral
regurgit
assess
effici
echocardiographi
lv
dilat
concomit
displac
papillari
muscl
caus
tether
mitral
leaflet
poor
valv
coaptat
closur
speckletrack
echocardiographi
imag
techniqu
analys
motion
tissu
heart
use
natur
occur
speckl
pattern
myocardium
promis
tool
identifi
presenc
inflammatori
infiltr
patient
dcm
fig
patient
biopsyproven
myocard
global
longitudin
strain
longitudin
shorten
percentag
provid
accur
assess
region
contractil
significantli
impair
compar
patient
without
inflamm
cardiac
mri
becom
increasingli
access
clinic
practic
repres
best
method
morpholog
function
evalu
character
myocardi
tissu
patient
dcm
fig
presenc
myocardi
fibrosi
detect
late
gadolinium
enhanc
lge
lge
distribut
may
indic
muscular
dystrophi
lge
presenc
pattern
quantif
may
assist
determin
risk
malign
ventricular
arrhyth
mia
mri
detect
myocardi
oedema
suggest
acut
myocard
sarcoidosi
inflammatori
diseas
granuloma
form
differ
organ
alongsid
cardiac
mri
ffluorodeoxyglucos
fdg
pet
emerg
valuabl
tool
diagnos
cardiac
sarcoidosi
howev
sensit
cardiac
mri
detect
inflamm
dcm
low
inflamm
scarc
stage
diseas
process
best
method
confirm
presenc
inflammatori
infiltr
dcm
histolog
andor
immunohistolog
addit
cardiac
mri
detect
presenc
viru
myocardium
futur
multicentr
prospect
studi
need
confirm
role
cardiac
mri
prognost
stratif
dcm
endomyocardi
biopsi
current
expert
consensu
statement
esc
recommend
patient
suspect
inflammatori
cardiomyopathi
undergo
emb
identifi
type
inflammatori
infiltr
determin
underli
aetiolog
form
aetiologybas
treatment
strategi
although
mani
centr
conduct
emb
basi
percept
procedur
carri
high
risk
complic
sever
studi
report
emb
perform
low
rate
major
complic
lv
biopsi
safe
right
ventricular
biopsi
tissu
obtain
emb
analys
use
histolog
immunohistochemistri
molecular
biolog
techniqu
histolog
examin
paraffin
section
variou
stain
protocol
use
detect
sever
morpholog
alter
myocardi
di
array
loss
parallel
align
cardiomyocyt
vacuol
format
cardiomyocyt
hypertrophi
myocytolysi
myofibrillar
degener
sub
lethal
injuri
cardiac
muscl
cell
necrosi
cell
death
scar
format
collagen
deposit
fibrosi
patholog
vascular
condit
granuloma
giant
cell
multinucl
cell
form
fusion
cell
character
major
inflammatori
subtyp
fig
use
immunohistochemistri
markedli
increas
abil
detect
cardiac
inflamm
biopsi
section
monoclon
antibodi
enabl
precis
character
quantif
local
differ
immun
cell
type
celladhes
molecul
determin
cell
composit
inflammatori
foci
affect
prognosi
dcm
establish
proport
type
immun
cell
crucial
decid
optim
type
treatment
microbi
genom
determin
quantifi
sequenc
use
pcrbase
method
includ
nest
revers
transcriptasepcr
quantit
pcr
activ
latent
infect
myocardium
differenti
parallel
blood
test
confirm
transcript
activ
emb
sampl
princip
virus
respons
inflammatori
cardio
myopathi
analys
viral
titr
serum
alon
use
diagnosi
correl
actual
phase
cardiomyopathi
final
novel
biomark
microrna
gene
express
profil
introduc
molecular
examin
emb
identif
distinct
gene
express
profil
myocardium
enabl
clear
discrimin
sampl
giant
cell
acut
myocard
inflamm
even
direct
histolog
proof
giant
cell
inflamm
moreov
diseasespecif
gene
express
profil
chang
effect
treatment
therebi
also
use
monitor
therapi
prognosi
poor
patient
dcm
lvef
right
ventricular
involv
nyha
function
class
iii
iv
box
sever
factor
worsen
prognosi
advers
remodel
characterist
dcm
includ
function
mitral
regurgit
leakag
blood
backward
mitral
valv
myocardi
fibrosi
dyssynchron
ventricular
contract
enlarg
chamber
addit
factor
affect
prognosi
persist
enteroviru
myocardium
associ
ventricular
dysfunct
wherea
viral
genom
clearanc
associ
improv
ventricular
function
prognosi
differ
virus
respond
differ
antivir
drug
sometim
complet
elimin
know
speci
fic
pathogen
viru
crucial
make
tailor
treatment
decis
clinic
experiment
studi
immunohistolog
evid
inflamm
identifi
independ
predictor
surviv
thu
precis
character
quantif
intramyocardi
immun
cell
subtyp
need
inform
decis
start
immunosuppress
therapi
goal
improv
prognosi
manag
dcm
aim
reduc
symptom
heart
failur
improv
cardiac
function
fig
sever
pharmacolog
option
devic
avail
pivot
random
control
clinic
trial
provid
evid
guidelin
treatment
heart
failur
reduc
eject
fraction
includ
larg
proport
patient
nonischaem
aetiolog
individu
probabl
develop
heart
failur
result
dcm
consequ
basi
subgroup
analys
reason
assum
efficaci
safeti
treatment
heart
failur
extend
patient
dcm
cours
investigatorreport
aetiolog
larg
clinic
trial
may
necessarili
accur
nonischaem
aetiolog
may
includ
sever
caus
heart
failur
addit
dcm
heart
failur
caus
hypertens
patient
advanc
diseas
pharmacolog
devic
therapi
may
insuffici
maintain
adequ
cardiac
function
surgeri
might
requir
two
major
option
heart
transplant
implant
longterm
mechan
circulatori
support
either
temporari
measur
await
transplant
perman
addit
surgic
approach
includ
correct
mitral
valv
regurgit
final
addit
aetiologybas
therapi
might
appropri
patient
embconfirm
myocard
infectionassoci
dcm
includ
immunosuppress
antivir
therapi
immunoadsorpt
therapi
remov
circul
autoantibodi
still
investig
evid
suggest
exercis
benefici
heart
failur
although
elderli
patient
enrol
studi
optimum
level
intens
exercis
prescrib
uncertain
furthermor
larg
trial
exercis
patient
heart
failur
hfaction
show
modest
treatment
effect
obtain
intens
train
regimen
may
practic
deliv
everi
healthcar
centr
importantli
exercis
contraind
activ
phase
inflammatori
cardiomyopathi
athlet
nonathlet
dcm
due
lamin
ac
mutat
pharmacolog
therapi
heart
failur
ace
inhibitor
angiotensin
receptor
antagonist
patient
develop
cough
advers
effect
ace
inhibitor
standard
drug
therapi
heart
failur
dcm
tabl
combin
angiotensin
receptorneprilysin
inhibitor
reduc
total
mortal
hospit
admiss
compar
ace
inhibitor
could
replac
ace
inhibitor
one
cornerston
drug
therapi
chronic
heart
failur
mineralocorticoid
antagonist
f
inhibitor
provid
increment
benefit
surviv
hospit
admiss
combin
ace
inhibitor
pharmacolog
therapi
use
accord
intern
guidelin
take
account
blood
pressur
heart
rate
rhythm
renal
function
blood
chemistri
cardiac
resynchron
therapi
crt
modal
cardiac
pace
use
patient
lv
systol
dysfunct
dyssynchron
ventricular
activ
provid
simultan
nearli
simultan
electr
activ
left
ventricl
right
ventricl
via
stimul
biventricular
pace
left
ventricl
alon
therapi
perform
either
crtpacemak
crtp
combin
crticd
addit
pacemak
function
deliv
electr
shock
reset
sinu
rhythm
case
arrhythmia
crt
devic
includ
transven
pace
lead
place
branch
coronari
sinu
less
commonli
epicardi
endocardi
lv
lead
lv
pace
addit
lead
right
ventricl
right
atrium
crt
indic
patient
heart
failur
lvef
life
expect
good
function
statu
year
sinu
rhythm
markedli
prolong
qr
durat
ms
ecg
show
left
bundl
branch
block
irrespect
symptom
sever
benefit
crt
patient
right
bundl
branch
block
interventricular
conduct
delay
unclear
subgroup
analys
suggest
littl
benefit
even
harm
two
random
placebocontrol
trial
comparison
medic
therapi
pace
defibril
heart
failur
companion
cardiac
resynchron
heart
failur
carehf
studi
random
patient
moder
sever
symptomat
heart
failur
nyha
class
iii
iv
either
optim
medic
therapi
optim
medic
therapi
plu
crt
trial
crt
reduc
risk
death
caus
hospit
admiss
worsen
heart
failur
rel
risk
ratio
death
crtp
crticd
crtd
companion
studi
crtp
carehf
studi
carehf
studi
rel
risk
ratio
hospit
crtp
trial
also
show
crt
improv
symptom
qualiti
life
qol
ventricular
function
similarli
two
random
placebocontrol
trial
evalu
effect
crt
patient
mild
symptom
nyha
class
heart
failur
maditcrt
trial
moder
symptom
nyha
class
ii
heart
failur
resynchron
defibril
ambulatori
heart
failur
trial
raft
patient
receiv
either
optim
medic
therapi
plu
icd
maintain
spontan
sinu
rhythm
optim
medic
therapi
plu
crtd
pace
control
icd
trial
crt
reduc
risk
primari
composit
end
point
death
heart
failur
hospit
rel
risk
ratio
maditcrt
rel
risk
ratio
raft
allcaus
mortal
significantli
reduc
raft
maditcrt
crt
improv
symptom
qol
ventricular
function
patient
popul
well
maditcrt
raft
show
signific
treatmentbysubgroup
interact
wherebi
qr
durat
modifi
treatment
effect
crt
seem
effect
patient
qr
ms
crt
benefici
patient
left
bundl
branch
block
right
bundl
branch
block
interventricular
conduct
defect
metaanalysi
mortal
benefit
crt
similar
individu
ischaem
diseas
nonischaem
cardiomyopathi
thu
trial
crt
reduc
risk
death
improv
symptom
qol
ventricular
function
definit
diagnosi
pathophysiolog
underli
dcm
prerequisit
specif
person
therapi
base
aetiolog
howev
treatment
guidelin
caus
inflammatori
dcm
miss
time
thu
multicentr
prospect
random
studi
test
immunosuppress
antivir
therapi
inflammatori
dcm
need
retrospect
analysi
show
immunosuppress
treatment
patient
embproven
virusposit
cardiomyopathi
deleteri
consequ
prospect
random
placebocontrol
studi
timictri
show
patient
embproven
chronic
virusneg
myocard
refractori
standard
therapi
immunosuppress
therapi
result
signific
improv
lvef
compar
placebo
indic
immunosuppress
therapi
effect
patient
inflammatori
dcm
result
subsequ
confirm
anoth
trial
ideal
immunosuppress
therapi
start
earli
possibl
irrevers
remodel
occur
viral
infect
frequent
caus
myocard
lead
inflammatori
dcm
individu
biopsybas
analysi
patient
myocard
presenc
viru
myocardium
associ
progress
impair
lv
function
wherea
spontan
viral
clearanc
associ
signific
improv
lv
function
consequ
nonrandom
studi
patient
enterovirusassoci
adenovirusassoci
cardiomyopathi
administr
significantli
reduc
viru
load
reduc
myocardi
injuri
improv
longterm
surviv
betainterferon
chronic
viral
cardiomyopathi
bicc
trial
viru
load
reduct
clearanc
significantli
higher
group
placebo
group
howev
treatment
statist
significantli
less
effect
clear
parvoviru
ref
final
small
openlabel
studi
found
remov
circul
autoantibodi
immunoadsorpt
improv
cardiac
function
decreas
myocardi
inflamm
howev
present
immunoadsorpt
still
experiment
treatment
option
conflict
result
regard
effect
placebocontrol
multicentr
studi
underway
test
therapi
patient
cardiomyopathi
tabl
current
risk
stratif
scheme
predict
lifethreaten
arrhythmia
patient
dcm
base
mainli
degre
systol
dysfunct
left
ventricl
lvef
set
threshold
high
risk
sudden
death
basi
result
random
clinic
trial
although
data
support
use
icd
robust
patient
ischaem
dcm
evid
random
trial
patient
nonischaem
dcm
debat
time
current
european
american
colleg
cardiologyamerican
heart
associ
guidelin
icd
implant
patient
nonischaem
dcm
base
metaanalysi
includ
trial
icd
implant
primari
prevent
sudden
cardiac
death
trial
icd
implant
secondari
prevent
measur
patient
surviv
episod
ventricular
fibril
demonstr
reduct
allcaus
mortal
icd
use
danish
trial
defibril
implant
patient
nonischem
systol
heart
failur
patient
nonischaem
dcm
optim
medic
therapi
crt
randomli
assign
icd
versu
icd
primari
prevent
sudden
cardiac
death
differ
allcaus
mortal
primari
end
point
observ
two
group
followup
result
danish
studi
might
explain
overal
low
mortal
control
group
possibl
justifi
high
use
crt
high
adher
optim
medic
therapi
group
may
reduc
power
studi
prove
efficaci
icd
nevertheless
remark
icd
group
show
reduct
incid
sudden
cardiac
death
also
box
nyha
classif
heart
failur
new
york
heart
associ
nyha
classif
combin
clinic
imag
biomark
indic
risk
heart
failur
class
symptom
limit
ordinari
physic
activ
short
breath
walk
climb
stair
mild
symptom
slight
limit
ordinari
activ
mark
limit
activ
due
symptom
even
ordinari
activ
walk
short
distanc
sever
limit
patient
experi
symptom
even
rest
overal
surviv
benefit
subgroup
patient
year
age
updat
metaanalysi
six
random
trial
assess
effect
icd
allcaus
mortal
patient
nonischaem
dcm
random
icd
optim
medic
therapi
primari
prevent
sudden
cardiac
death
found
signific
risk
reduct
allcaus
mortal
icd
arm
interestingli
result
remain
relev
statist
signific
elimin
contribut
trial
involv
patient
crtd
reduct
allcaus
mortal
icd
problem
use
lvef
pivot
risk
marker
patient
dcm
singl
paramet
recapitul
complex
diseas
aris
number
differ
aetiolog
avail
genotypephenotyp
studi
patient
dcm
enabl
physician
identifi
popul
increas
risk
sudden
cardiac
death
patient
mutat
lmna
fnlc
increas
avail
person
aetiolog
diagnosi
patient
dcm
possibl
provid
morerefin
risk
stratif
scheme
addit
lvef
take
account
genet
inform
addit
clinic
paramet
possibl
combin
multiparametr
score
promis
approach
risk
stratif
includ
assess
lge
cardiac
mri
cardiac
sympathet
nerv
function
metaiodobenzylguanidin
label
mibg
healthrel
qol
patient
dcm
poorli
analys
mani
patient
dcm
progress
chronic
heart
failur
patient
awar
risk
die
advers
effect
therapi
frequent
hospit
consider
neg
effect
patient
qol
recent
studi
identifi
three
factor
predict
posit
selfcar
complianc
treatment
clear
inform
medic
belief
ill
seriou
consequ
effect
medic
use
lifestyl
moreov
previou
studi
show
signific
improv
aspect
qol
comprehens
cardiac
rehabilit
daili
light
exercis
weight
manag
programm
nursel
patient
educ
thu
import
way
improv
qol
patient
dcm
provid
earli
pathophysiologicalbas
diagnosi
better
risk
stratif
ultim
person
therapi
base
aetiolog
assess
diseas
mani
advanc
made
improv
diagnosi
better
character
dcm
basi
underli
aetiolog
advanc
understand
pathogenesi
diseas
deriv
larg
preclin
anim
model
howev
mani
gap
understand
remain
clinic
care
could
improv
har
novel
advanc
imag
modal
dcm
identifi
util
novel
serum
biomark
improv
understand
relationship
infect
inflamm
autoimmun
cardiac
damag
remodel
pathogenesi
dcm
take
advantag
new
therapeut
opportun
cardiac
regener
refin
current
diagnost
tool
imag
modal
could
revolution
understand
pathogenesi
diseas
fdgpet
import
tool
better
understand
relationship
cardiac
inflamm
develop
dcm
use
preclin
mous
model
myocard
advanc
detect
cardiac
inflamm
new
imag
marker
anim
studi
success
detect
inflamm
patient
myocard
could
refin
detect
inflamm
patient
dcm
inflammatori
cell
often
scarc
echocardiographi
establish
method
assess
systol
dysfunct
advanc
echocardiographi
techniqu
measur
global
longitudin
strain
tissu
doppler
strain
speckletrack
echocardiographi
potenti
enabl
much
earlier
detect
systol
dysfunct
lead
dcm
especi
echocardiographi
result
pair
serum
biomark
heart
failur
bnp
prontbnp
solubl
receptorlik
also
known
creactiv
protein
crp
clinic
manag
patient
symptomat
dilat
cardiomyopathi
start
standard
heart
failur
medic
haemodynam
improv
treatment
continu
care
followup
monitor
progress
left
ventricular
dysfunct
left
ventricular
dysfunct
note
lack
haemodynam
improv
endomyocardi
biopsi
perform
viral
infect
detect
revers
transcriptasepcr
immunohistochemistri
stain
patient
may
receiv
antivir
therapi
certain
inflammatori
cell
discov
tailor
immunosuppress
therapi
may
administ
haemodynam
improv
addit
treatment
option
heart
failur
explor
metaanalysi
four
trial
therapi
reduc
allcaus
mortal
patient
ischaem
diseas
nonischaem
cardiomyopathi
neprilysin
inhibit
prevent
breakdown
numer
vasoact
substanc
includ
natriuret
peptid
vasodil
promot
renal
sodium
water
excret
inhibit
patholog
growth
hypertrophi
fibrosi
paradigmhf
trial
compar
sacubitril
neprilysin
inhibitor
valsartan
angiotensin
receptor
inhibitor
combin
enalapril
ace
inhibitor
primari
end
point
composit
death
cardiovascular
caus
heart
failur
hospit
occur
patient
sacubitrilvalsartan
group
patient
enalapril
group
mortal
significantli
reduc
patient
receiv
sacubitrilvalsartan
recommend
symptomat
patient
addit
treatment
ace
inhibitor
lvef
rale
mortal
benefit
spironolacton
similar
patient
ischaem
nonischaem
diseas
emphasishf
hazard
ratio
primari
composit
end
point
death
cardiovascular
caus
heart
failur
hospit
significantli
differ
patient
ischaem
aetiolog
patient
nonischaem
cardiomyopathi
nitrat
hydralazin
combin
nitrat
hydralazin
vasodil
drug
aheft
trial
examin
safeti
efficaci
fixeddos
combin
therapi
isosorbid
dinitr
hydralazin
hydrochlorid
combin
ace
inhibitor
arb
mra
african
american
nyha
class
iii
iv
heart
failur
popul
chosen
retrospect
subgroup
analysi
earlier
trial
treatment
combin
produc
clear
evid
benefit
overal
suggest
africanamerican
patient
benefit
aheft
trial
stop
earli
treatment
drug
combin
led
signific
reduct
allcaus
mortal
treatment
effect
mortal
similar
patient
without
ischaem
aetiolog
f
inhibitor
reduct
heart
rate
inhibit
pacemak
current
european
medicin
agenc
approv
ivabradin
use
europ
patient
lvef
sinu
rhythm
rest
heart
rate
bpm
group
ivabradin
confer
surviv
benefit
shift
trial
ivabradin
significantli
reduc
primari
composit
outcom
cardiovascular
death
heart
failur
hospit
reduc
cardiovascular
death
allcaus
death
hazard
ratio
primari
composit
end
point
higher
although
significantli
patient
ischaem
diseas
nonischaem
diseas
inotrop
agent
increas
forc
contract
recommend
patient
sustain
atrial
fibril
refractori
heart
failur
symptom
digitali
investig
group
trial
digoxin
reduc
allcaus
mortal
primari
end
point
lead
significantli
reduc
rel
risk
heart
failur
hospit
devic
therapi
heart
failur
crt
cardiac
pace
patient
left
ventricular
systol
dysfunct
dyssynchron
ventricular
activ
qr
durat
ms
crt
improv
cardiac
perform
appropri
select
patient
improv
symptom
wellb
reduc
morbid
mortal
aetiologybas
therapi
immunosuppress
virusneg
inflammatori
cardiomyopathi
chronic
myocard
prospect
random
placebocontrol
timictri
immunosuppress
result
signific
improv
lvef
compar
placebo
bicc
trial
viru
load
reduct
clearanc
significantli
higher
group
placebo
group
ace
angiotensinconvert
enzym
arb
angiotensin
receptor
blocker
bicc
betainterferon
chronic
viral
cardiomyopathi
crt
cardiac
resynchron
therapi
lvef
left
ventricular
eject
fraction
mra
mineralocorticoid
receptor
antagonist
nyha
new
york
heart
associ
advanc
genet
sequenc
molecular
analysi
gene
protein
involv
pathogenesi
dcm
preclin
anim
model
human
studi
unveil
promis
new
serum
biomark
use
indic
risk
heart
failur
prognosi
also
reveal
underli
patholog
therebi
inform
treatment
elev
serum
level
correl
sever
heart
failur
nyha
class
patient
myocard
dcm
well
cardiovascular
condit
cytokin
induc
biomechan
strain
cardiac
fibroblast
cardiomyocyt
vascular
endotheli
cell
small
studi
significantli
higher
patient
dcm
control
found
predict
risk
develop
heart
failur
patient
dcm
sever
recent
studi
combin
ntprobnp
releas
condit
pressur
overload
therefor
marker
heart
failur
serum
level
provid
addit
valu
predict
sudden
death
patient
heart
failur
lvef
two
import
process
heart
failur
inflamm
renal
impair
increas
serum
immunoglobulin
free
light
chain
flc
concentr
sum
circul
flc
increas
patient
autoimmun
diseas
dcm
amat
unpublish
result
communitybas
studi
individu
gener
popul
show
high
flc
concentr
associ
increas
risk
allcaus
mortal
flc
especi
increas
patient
myocard
associ
mortal
amat
unpublish
result
combin
flc
sum
flc
shown
associ
high
combin
flc
prognosi
provid
increment
prognost
valu
multipl
biomark
patient
recent
hospit
decompens
heart
failur
mechan
flc
increas
dcm
heart
failur
remain
clarifi
flc
may
promis
new
biomark
inflamm
dcm
infect
futur
studi
also
aim
better
understand
relationship
viral
parasit
infect
trypanosoma
cruzi
infect
develop
dcm
infect
remain
endem
mani
countri
probabl
contribut
emerg
public
health
burden
dcm
particular
import
determin
relationship
infect
host
immun
respons
context
host
genet
addit
hepat
hepat
c
viru
hcv
infect
frequent
caus
cardiac
renal
abnorm
includ
hypertroph
cardiomyopathi
dcm
egypt
patient
hcv
infect
echocardiograph
abnorm
frequent
found
dilat
left
atrium
dilat
hypertrophi
left
ventricl
disturb
diastol
systol
function
left
ventricl
china
ntprobnp
level
higher
patient
hcvinfectionassoci
hepat
hepat
b
viru
infect
healthi
control
associ
major
histocompat
complex
mhc
antigen
hcv
clearanc
suscept
identifi
molecular
mechan
behind
develop
cardiomyopathi
hcv
infect
relat
mhc
class
ii
molecul
found
differ
dcm
hypertroph
cardiomyopathi
antivir
treatment
hcv
infect
report
improv
renal
cardiovascular
outcom
patient
diabet
mellitu
annual
number
death
associ
hcv
higher
nation
notifi
infecti
condit
usa
suggest
viral
infect
could
make
import
contribut
dcm
case
develop
countri
mechan
hcv
caus
dcm
remain
elucid
autoimmun
preclin
clinic
evid
support
form
dcm
result
pathogenet
autoimmun
respons
mice
lack
cell
receptor
costimulatori
receptor
program
cell
death
protein
spontan
develop
autoimmun
dcm
autoantibodi
bind
cardiac
troponin
passiv
transfer
monoclon
antibodi
direct
cardiac
troponin
induc
cardiac
dysfunct
antibodi
cardiac
troponin
found
patient
myocard
dcm
presenc
biomark
probabl
reflect
damag
cardiac
muscl
futur
experiment
clinic
studi
need
clarifi
role
autoimmun
autoantibodi
pathogenesi
dcm
serum
autoantibodi
may
form
inexpens
earli
screen
method
determin
subset
patient
increas
risk
develop
dcm
clinic
anim
studi
also
need
find
novel
therapi
improv
efficaci
safeti
case
embproven
virusneg
autoimmun
dcm
without
serum
cardiacspecif
autoantibodi
rapidli
emerg
promis
new
area
medicin
potenti
regener
damag
scar
heart
tissu
patient
dcm
care
improv
cardiovascular
medicin
improv
reperfus
therapi
implant
defibril
novel
medic
cardiac
transplant
mortal
decreas
advanc
area
particularli
import
dcm
diseas
often
detect
end
stage
scar
tissu
well
establish
refractori
medic
revers
process
promis
new
tool
includ
mesenchym
stem
cell
purifi
platelet
exosom
product
fatderiv
extracellular
vesicl
other
extracellular
vesicl
morepurifi
form
term
exosom
deriv
cell
adipocyt
platelet
healthi
individu
import
celltocel
commun
found
contain
mani
regulatori
factor
protein
rna
lipid
inhibit
proinflammatori
profibrot
patholog
although
mani
therapi
yet
appli
patient
dcm
clinic
set
hold
promis
therapi
could
prevent
revers
remodel
promot
cardiac
regener
publish
onlin
xx
xx
xxxx
